Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Healthlead PCLBKK:HL 73 EV-to-EBITDA is 5.29 as of Sep. 21, 2026, which is 65% below its 10-year median of 15.31. GuruFocus rates BKK:HL with a GF Score™ of 73/100 and a GF Value™ of ฿10.11 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 523 Healthcare Providers & Services companies, Healthlead PCL ranks better than 81.45% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Healthlead PCL's enterprise value is ฿1,004 Mil.
Healthlead PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ฿190 Mil. Therefore, Healthlead PCL's EV-to-EBITDA for today is 5.29.
The historical rank and industry rank for Healthlead PCL's EV-to-EBITDA or its related term are showing as below:
BKK:HL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.27 Med: 15.31 Max: 49.09
Current: 5.3
During the past 8 years, the highest EV-to-EBITDA of Healthlead PCL was 49.09. The lowest was 5.27. And the median was 15.31.
BKK:HL's EV-to-EBITDA is ranked better than 81.45% of 523
companies
in the Healthcare Providers & Services industry
Industry Median: 10.09
vs BKK:HL: 5.30
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Healthlead PCL's PE Ratio (TTM) for today is calculated as:
Healthlead PCL's share price for today is ฿4.50.
Healthlead PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿0.225.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Healthlead PCL's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Healthlead PCL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healthlead PCL EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Healthlead PCL's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Healthlead PCL's EV-to-EBITDA falls into.
Healthlead PCL's current Enterprise Value is ฿1,004 Mil.
Healthlead PCL's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿190 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healthlead PCL (BKK:HL) has a EV-to-EBITDA of 5.29 as of Sep. 21, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Healthlead PCL. This is 65% below median its historical median of 15.31. Over the past decade, Healthlead PCL's EV-to-EBITDA has ranged from 5.27 to 49.09. According to the industry distribution chart, Healthlead PCL ranks #97 out of 523 companies in the Healthcare Providers & Services industry, placing it in the top 18.5%.
Is Healthlead PCL's EV-to-EBITDA too high?
Healthlead PCL's current EV-to-EBITDA of 5.29 is 65% below median its 10-year median of 15.31. Over the past 10 years, this metric has ranged from a low of 5.27 to a high of 49.09. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.09. Healthlead PCL's value of 5.29 is 47.6% below this industry median. Based on the distribution chart, Healthlead PCL ranks #97 out of 523 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Healthlead PCL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthlead PCL's EV-to-EBITDA compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Healthlead PCL ranks #97 out of 523 companies for EV-to-EBITDA. This places Healthlead PCL in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 10.09. Healthlead PCL's value of 5.29 is 47.6% below this benchmark. Historically, Healthlead PCL's own EV-to-EBITDA has ranged from 5.27 to 49.09 over the past decade. While the company's 10-year median is 15.31 vs. the industry median of 10.09, Healthlead PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.09, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Healthlead PCL's current EV-to-EBITDA of 5.29 is 47.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Healthlead PCL. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Healthlead PCL's current EV-to-EBITDA is 5.29, which is 65% below median its own 10-year median of 15.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthlead PCL stock overvalued right now?
Based on GuruFocus' analysis, Healthlead PCL (BKK:HL) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿10.11, compared to a current price of ฿4.50 — trading 55.5% below its estimated fair value. The current EV-to-EBITDA is 5.29, which is 65% below median its 10-year median of 15.31 and 47.6% below the Healthcare Providers & Services industry median of 10.09. Healthlead PCL's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Healthlead PCL (BKK:HL), the current EV-to-EBITDA is 5.29 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healthlead PCL (BKK:HL) Overvalued in 2026?
Based on GuruFocus' analysis, Healthlead PCL stock appears to be undervalued.
The current stock price of ฿4.50 is trading 55.5% below its estimated GF Value™ of ฿10.11.
GuruFocus considers Healthlead PCL to be Significantly Undervalued.
Key valuation signals for BKK:HL:
EV-to-EBITDA: 5.29 (65% below median its 10-year median of 15.31)
GF Value™: ฿10.11 vs. price of ฿4.50 (55.5% below fair value)
Industry Position: 47.6% below the Healthcare Providers & Services median (#97 of 523)
No single metric tells the full story. See the BKK:HL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healthlead PCL is a holding company. Along with its subsidiaries, it operates a pharmacy business under iCare, Pharmax, vitaminclub, and Super Drug brands, distributing medicines, medical supplies, cosmeceuticals, dietary supplements, medical devices, and other healthcare products. Additionally, it is involved in co-inventing and co-developing healthcare products in collaboration with external research teams and contract manufacturers, producing and distributing its own branded products. Geographically, the group operates only in Thailand.
73GF Score
Get the complete analysis for BKK:HL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:HL has been successfully added to your 
